Vascular Endothelial Growth Factor in Alloimmunity

同种免疫中的血管内皮生长因子

• 批准号: 6649605
• 负责人: JESSE A FLAXENBURG
• 金额: $ 4.99万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6649605
• 关键词: CD40 molecule; IP 10 protein; JAK kinase; SDS polyacrylamide gel electrophoresis; acute disease /disorder; biological signal transduction; chemokine; chronic disease /disorder; enzyme linked immunosorbent assay; heart transplantation; histocompatibility; hormone regulation /control mechanism; human tissue; immunoprecipitation; inflammation; postdoctoral investigator; tissue /cell culture; transplant rejection; transplantation immunology; vascular endothelial growth factors; western blottings

DESCRIPTION (provided by the applicant): Transplant patients are currently subjected to long term morbid therapy with immunosuppressive medications in order to prevent rejection of their grafts. For this reason, it is critical to devise therapies that are more specific and have improved side effect profiles. This will require a greater understanding into the mechanisms of allograft rejection. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor known. An underappreciated biologic function of VEGF is its role in initiating and perpetuating an inflammatory response through the induction of proinflammatory chemokines. Furthermore, this function of VEGF has major implications for alloimmune recognition. This proposal seeks to elucidate the mechanisms by VEGF can exert an inflammatory response in the setting of alloimmune stimulation. The understanding gained through these experiments is likely to uncover new, more specific targets for the treatment of allograft rejection.

描述（由申请人提供）：移植患者目前正在接受免疫抑制药物的长期病态治疗，以防止拒绝其移植物。因此，设计更具体并改善副作用曲线的疗法至关重要。这将需要对同种异体移植排斥的机制有更深入的了解。血管内皮生长因子（VEGF）是已知的最有效的血管生成因子。 VEGF的生物学功能不足，是通过诱导促炎性趋化因子来启动和永久炎症反应的作用。此外，VEGF的这一功能对同种免疫识别具有重大影响。该提议旨在通过VEGF阐明机制，可以在同种免疫刺激的情况下发挥炎症反应。通过这些实验获得的理解很可能会发现新的，更具体的靶标，以治疗同种异体移植排斥。